Tagged with GE

Switzerland Fabrice Véricel and Geoffrey Folie explore UCB’s strategic growth, highlighting its European sites in Braine-l’Alleud, Belgium and Bulle, Switzerland and their roles in global pharmaceutical production. Key topics include the transition to biologics, embracing AI for process optimization, and sustainability initiatives.   Biomanufacturing thrives on complexity and collaboration, offering intellectual…

Switzerland Hendrik von Waldburg, Country Manager of Angelini Pharma S.p.A., Rom, Zweigniederlassung Zug, shares insights into the company’s ambitious vision for brain health and its expanding presence in the Swiss market. With a strong background in CNS and a focus on innovative therapies, Hendrik discusses the challenges and opportunities of building…

Mexico Rogerio Peso outlines how Viatris leverages collaborations to address critical healthcare needs in Mexico, combining its strengths with other stakeholders to improve patient outcomes. With a mission to offer high-quality, affordable medicines, Peso also points out how Viatris aligns its portfolio with the healthcare needs of Latin America, addressing gaps…

China An overview of some of the top stories from China’s pharma industry, including the arrest of AstraZeneca China’s top executive; Pfizer’s USD 1 billion China investment; WuXi AppTec’s continuing revenue decline, and Aditum Bio and Leads Biolabs’ creation of autoimmune disease-focused Oblenio Bio. AstraZeneca’s China chief in custody, believes unrelated…

Switzerland Michael Kubischik shares his career journey and Sanofi’s strategic focus in Switzerland. He highlights Sanofi’s dedication to become the world´s leading immunology company, supported by initiatives like AI integration and efficient regulatory processes to improve patient access, as well as the benefits of working for a company with such a…

Mexico Emily Morris, head of Sanofi in Latin America discusses the company’s transformative journey under the 2019-initated ‘Play to Win’ strategy. With an emphasis on optimizing their portfolio and prioritizing immunoscience, she highlights Sanofi’s commitment to leveraging AI to enhance patient access to innovative therapies. Morris also delves into the importance…

Global Traditional drug discovery is fraught with failure and often like trying to find a needle in a haystack. Even once a candidate is identified, the development process takes thousands of man-hours and generally billions of dollars. Artificial Intelligence has the potential to change this paradigm. It can aggregate and synthesize…

Switzerland Myriam DeLeone, General Manager of Amgen Switzerland, discusses the company’s commitment to tackling diseases prevalent in Switzerland such cardiovascular diseases and osteoporosis, Amgen’s expanding biosimilars profile, and how the company is leveraging Artificial Intelligence (AI), particularly to optimize drug development. DeLeone also comments on Switzerland’s concerning deficiencies in digitalization and access,…

UK A roundup of top stories from UK pharma and healthcare, including the innovative manufacturing fund comprised in the government’s new life-sciences-focused budget; GSK’s autoimmune therapy deal with Chimagen Biosciences; Northern Ireland’s potential post-Brexit drug shortages, and Oxford Biomedica’s reband as OXB.   UK to create world-first ‘early warning system’ for…

USA Focused on rare and ultra-rare genetic diseases, Ultragenyx identifies itself as the industry’s most productive company working in the field of high un-met need diseases. With no fewer than four products approved across five indications, a blockbuster therapy that reached 2023 revenues of USD 328 million, and six candidates in…

Saudi Arabia The latest pharmaceutical industry and healthcare news from the Middle East and Africa (MEA), including Eva Pharma’s rheumatoid arthritis deal with Eli Lilly; Avalon Pharmaceuticals’ global expansion ambitions; the agreement between Lifera and Novo Nordisk for Saudi insulin production;Kelix Bio’s four pharma acquisitions, and Aspen’s EUR 500 million financing package…

Switzerland Miro Venturi, Executive Chairman at Stragen, explores the company’s strategic focus on addressing critical healthcare challenges, particularly drug shortages, while emphasizing its commitment to expanding its product portfolio in critical care and women’s health. Venturi highlights Stragen’s international culture, flexibility, and strong partnerships, positioning the company as a significant player…